Jagsonpal Pharmaceuticals Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Jagsonpal Pharmaceuticals.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth	17.5%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

No updates

Recent updates

Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) May Have Run Too Fast Too Soon With Recent 25% Price Plummet

Jan 14

Some Confidence Is Lacking In Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) As Shares Slide 25%

Jan 14

Some Confidence Is Lacking In Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) P/E

Oct 14

There May Be Some Bright Spots In Jagsonpal Pharmaceuticals' (NSE:JAGSNPHARM) Earnings

May 27

There's Reason For Concern Over Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) Massive 27% Price Jump

Apr 30

A Look At The Fair Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Apr 05

Investor Optimism Abounds Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) But Growth Is Lacking

Feb 06

Estimating The Intrinsic Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Jul 29

A Look At The Intrinsic Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

May 13

Does Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) Deserve A Spot On Your Watchlist?

Jul 05

A Look At The Fair Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Jun 13

Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) 0.6% Dividend Yield Looks Pretty Interesting

Apr 19

Should You Be Adding Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) To Your Watchlist Today?

Mar 21

Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) Stock Is Going Strong: Have Financials A Role To Play?

Feb 08

The Attractive Combination That Could Earn Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) A Place In Your Dividend Portfolio

Jan 08

Here's Why I Think Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) Is An Interesting Stock

Dec 21

Are Jagsonpal Pharmaceuticals's (NSE:JAGSNPHARM) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Nov 30

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Jagsonpal Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NSEI:JAGSNPHARM - Analysts future estimates and past financials data (INR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2024	2,536	523	N/A	N/A	N/A
9/30/2024	2,269	243	573	575	N/A
6/30/2024	2,100	203	N/A	N/A	N/A
3/31/2024	2,087	225	349	352	N/A
12/31/2023	2,207	245	N/A	N/A	N/A
9/30/2023	2,336	283	492	498	N/A
6/30/2023	2,363	313	N/A	N/A	N/A
3/31/2023	2,367	267	463	467	N/A
12/31/2022	2,410	223	N/A	N/A	N/A
9/30/2022	2,348	198	-2	-1	N/A
6/30/2022	2,326	131	N/A	N/A	N/A
3/31/2022	2,176	189	59	69	N/A
12/31/2021	2,168	247	N/A	N/A	N/A
9/30/2021	2,194	247	308	316	N/A
6/30/2021	2,163	214	N/A	N/A	N/A
3/31/2021	1,879	171	278	282	N/A
12/31/2020	1,746	135	N/A	N/A	N/A
9/30/2020	1,595	104	200	210	N/A
6/30/2020	1,450	84	N/A	N/A	N/A
3/31/2020	1,586	79	100	119	N/A
12/31/2019	1,675	93	N/A	N/A	N/A
9/30/2019	1,673	88	N/A	N/A	N/A
6/30/2019	1,697	85	N/A	N/A	N/A
3/31/2019	1,668	72	286	309	N/A
12/31/2018	1,611	30	N/A	N/A	N/A
9/30/2018	1,573	-10	N/A	N/A	N/A
6/30/2018	1,421	-66	N/A	N/A	N/A
3/31/2018	1,266	-116	N/A	-16	N/A
12/31/2017	1,234	-95	N/A	N/A	N/A
9/30/2017	1,193	26	N/A	N/A	N/A
6/30/2017	1,305	70	N/A	N/A	N/A
4/1/2017	1,441	119	N/A	-32	N/A
12/31/2016	1,534	131	N/A	N/A	N/A
9/30/2016	1,537	35	N/A	N/A	N/A
6/30/2016	1,466	34	N/A	N/A	N/A
3/31/2016	1,435	33	N/A	90	N/A
12/31/2015	1,434	13	N/A	N/A	N/A
9/30/2015	1,412	10	N/A	N/A	N/A
6/30/2015	1,412	9	N/A	N/A	N/A
3/31/2015	1,382	12	N/A	43	N/A
12/31/2014	1,306	23	N/A	N/A	N/A
9/30/2014	1,359	32	N/A	N/A	N/A
6/30/2014	1,397	28	N/A	N/A	N/A
3/31/2014	1,439	21	N/A	75	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if JAGSNPHARM's forecast earnings growth is above the savings rate (6.7%).

Earnings vs Market: Insufficient data to determine if JAGSNPHARM's earnings are forecast to grow faster than the Indian market

High Growth Earnings: Insufficient data to determine if JAGSNPHARM's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if JAGSNPHARM's revenue is forecast to grow faster than the Indian market.

High Growth Revenue: Insufficient data to determine if JAGSNPHARM's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if JAGSNPHARM's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/24 22:46
End of Day Share Price	2025/01/24 00:00
Earnings	2024/12/31
Annual Earnings	2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Jagsonpal Pharmaceuticals Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution

Jagsonpal Pharmaceuticals Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Third quarter 2025 earnings released: EPS: ₹4.74 (vs ₹0.59 in 3Q 2024)

Now 21% overvalued after recent price rise

Jagsonpal Pharmaceuticals Limited to Report Q3, 2025 Results on Jan 22, 2025

Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) May Have Run Too Fast Too Soon With Recent 25% Price Plummet

Some Confidence Is Lacking In Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) As Shares Slide 25%

High number of new and inexperienced directors

Jagsonpal Pharmaceuticals Limited Announces Resignation of Ashish Lakhotia as Chief Financial Officer

Jagsonpal Pharmaceuticals Limited to Report Q2, 2025 Results on Oct 23, 2024

Some Confidence Is Lacking In Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) P/E

Investor sentiment improves as stock rises 16%

Upcoming dividend of ₹5.00 per share

Jagsonpal Pharmaceuticals Limited, Annual General Meeting, Sep 18, 2024

First quarter 2025 earnings released: EPS: ₹1.94 (vs ₹2.85 in 1Q 2024)

Jagsonpal Pharmaceuticals Limited to Report Q1, 2025 Results on Aug 07, 2024

Investor sentiment improves as stock rises 16%

New minor risk - Market cap size

There May Be Some Bright Spots In Jagsonpal Pharmaceuticals' (NSE:JAGSNPHARM) Earnings

Full year 2024 earnings released: EPS: ₹8.49 (vs ₹10.20 in FY 2023)

There's Reason For Concern Over Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) Massive 27% Price Jump

Investor sentiment improves as stock rises 16%

A Look At The Fair Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Now 20% undervalued after recent price drop

Investor Optimism Abounds Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) But Growth Is Lacking

New minor risk - Market cap size

Third quarter 2024 earnings released: EPS: ₹1.48 (vs ₹2.97 in 3Q 2023)

Jagsonpal Pharmaceuticals Limited Announces Chief Financial Officer Changes

Jagsonpal Pharmaceuticals Limited to Report Q3, 2023 Results on Feb 01, 2024

Now 20% undervalued after recent price drop

Now 23% undervalued after recent price drop

Now 20% undervalued after recent price drop

Second quarter 2024 earnings released: EPS: ₹2.84 (vs ₹3.97 in 2Q 2023)

Jagsonpal Pharmaceuticals Limited to Report Q2, 2024 Results on Nov 03, 2023

Upcoming dividend of ₹5.00 per share at 1.1% yield

Jagsonpal Pharmaceuticals Limited, Annual General Meeting, Aug 31, 2023

First quarter 2024 earnings released: EPS: ₹2.85 (vs ₹0.14 in 1Q 2023)

Estimating The Intrinsic Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Jagsonpal Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 02, 2023

Full year 2023 earnings released: EPS: ₹10.20 (vs ₹7.48 in FY 2022)

Jagsonpal Pharmaceuticals Limited Recommends Dividend for the Financial Year Ended March 31, 2023

Investor sentiment improves as stock rises 15%

Jagsonpal Pharmaceuticals Limited Announces Appointment of Abhishek Joshi as Company Secretary and Compliance Officer

Third quarter 2023 earnings released: EPS: ₹2.97 (vs ₹2.06 in 3Q 2022)

Jagsonpal Pharmaceuticals Limited Announces Executive Changes

Investor sentiment improved over the past week

High number of new and inexperienced directors

Second quarter 2023 earnings released: EPS: ₹3.97 (vs ₹2.79 in 2Q 2022)

High number of new and inexperienced directors

Jagsonpal Pharmaceuticals Limited, Annual General Meeting, Sep 14, 2022

First quarter 2023 earnings released: EPS: ₹0.14 (vs ₹2.61 in 1Q 2022)

Jagsonpal Pharmaceuticals Limited to Report Q1, 2023 Results on Aug 09, 2022

High number of new and inexperienced directors

Full year 2022 earnings released: EPS: ₹748 (vs ₹6.51 in FY 2021)

Jagsonpal Pharmaceuticals Limited to Report Q4, 2022 Results on May 30, 2022

Investor sentiment improved over the past week

A Look At The Intrinsic Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Jagsonpal Pharmaceuticals Limited Announces Resignation of Sanjiv Kumar Dudeja as Chief Financial Officer

Investor sentiment improved over the past week

Upcoming dividend of ₹4.00 per share

Second quarter 2022 earnings released: EPS ₹2.79 (vs ₹1.53 in 2Q 2021)

Upcoming dividend of ₹1.00 per share

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

First quarter 2022 earnings released: EPS ₹2.61 (vs ₹0.96 in 1Q 2021)

Investor sentiment improved over the past week

Does Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) Deserve A Spot On Your Watchlist?

Full year 2021 earnings released: EPS ₹6.51 (vs ₹3.00 in FY 2020)

Investor sentiment improved over the past week

A Look At The Fair Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) 0.6% Dividend Yield Looks Pretty Interesting